Senzime initiates clinical study with CliniSenz System
Uppsala, May 31, 2017. Senzime AB (publ) initiates a clinical trial with CliniSenz for monitoring of tissue lactate levels after surgery in patients with esophageal cancer, a disease that affects approximately 500,000 patients worldwide annually. The current treatment is mostly surgical with risk of multiple operations and increased mortality. With CliniSenz System, it is possible to monitor the healing process after surgery and detect complications at an early stage. The study has been approved by the Ethics Committee and is expected to start in the beginning of June 2017.
Senzime has developed user-friendly products for continuous monitoring of glucose and lactate in fluids such as blood and tissues. These measurements are important —and often critical—for patients who have undergone surgery and who are at risk for complications such as ischemia (lack of oxygen) and anastomotic (bowel connection) leakage.
CliniSenz System incorporates the OnZurf Probe and CliniSenz Analyzer. The system makes it possible to continuously analyze micro-environment samples from the surface of an organ. CliniSenz system will be used in a study of patients who had surgery for esophageal cancer (esophageal resection), a surgical procedure that is performed on half a million patients worldwide every year. In Sweden, tens of thousands of cancer operations are conducted annually, and an effective monitoring system can help to reduce the number of painful and serious complications that increase the cost of treatment.
"The clinical market is looking for systems that allow continuous monitoring of biomarkers in blood and tissues to rapidly detect postoperative complications and to guide timely interventions. Effective monitoring systems are necessary in order to reduce the number of painful and care-intensive complications after surgery," says Lena Söderström, CEO of Senzime AB.
The clinical study involves patients who had operations for cancer of the esophagus, and initial assessments are expected after enrolling 20 patients. The study is conducted at the Uppsala University Hospital under the direction of Professor Magnus Sundbom, a renowned surgeon who specializes in the treatment of esophageal cancer and upper abdominal surgery.
"We are very interested in following the lactate levels locally in the esophagus after surgery and detect early signs of leakage before being detected by conventional diagnostics. Early detection creates the conditions for rapid intervention and the opportunity to prevent complications after surgery, "says Dr Magnus Sundbom, Uppsala University Hospital.
For further information, please contact:
Lena Söderström, CEO
Tel: +46-70-816 39 12 email: lena.soderstrom@senzime.com
TO THE EDITORS
About Senzime
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com